Literature DB >> 19528537

Spatiotemporal regulation of intracellular trafficking of Toll-like receptor 9 by an inhibitory receptor, Ly49Q.

Mariko Yoshizaki1, Aya Tazawa, Eiji Kasumi, Shigemi Sasawatari, Kenji Itoh, Taeko Dohi, Takehiko Sasazuki, Kayo Inaba, Andrew P Makrigiannis, Noriko Toyama-Sorimachi.   

Abstract

Toll-like receptor (TLR) 9 recognizes unmethylated microorganismal cytosine guanine dinucleotide (CpG) DNA and elicits innate immune responses. However, the regulatory mechanisms of the TLR signaling remain elusive. We recently reported that Ly49Q, an immunoreceptor tyrosine-based inhibitory motif-bearing inhibitory receptor belonging to the natural killer receptor family, is crucial for TLR9-mediated type I interferon production by plasmacytoid dendritic cells. Ly49Q is expressed in plasmacytoid dendritic cells, macrophages, and neutrophils, but not natural killer cells. In this study, we showed that Ly49Q regulates TLR9 signaling by affecting endosome/lysosome behavior. Ly49Q colocalized with CpG in endosome/lysosome compartments. Cells lacking Ly49Q showed a disturbed redistribution of TLR9 and CpG. In particular, CpG-induced tubular endolysosomal extension was impaired in the absence of Ly49Q. Consistent with these findings, cells lacking Ly49Q showed impaired cytokine production in response to CpG-oligodeoxynucleotide. Our data highlight a novel mechanism by which TLR9 signaling is controlled through the spatiotemporal regulation of membrane trafficking by the immunoreceptor tyrosine-based inhibitory motif-bearing receptor Ly49Q.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528537     DOI: 10.1182/blood-2008-12-192344

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  TLR7/9 versus TLR3/MDA5 signaling during virus infections and diabetes.

Authors:  Melissa Swiecki; Stephen A McCartney; Yaming Wang; Marco Colonna
Journal:  J Leukoc Biol       Date:  2011-08-15       Impact factor: 4.962

Review 2.  Cis-trans interactions of cell surface receptors: biological roles and structural basis.

Authors:  Werner Held; Roy A Mariuzza
Journal:  Cell Mol Life Sci       Date:  2011-08-24       Impact factor: 9.261

3.  Type I interferons: diversity of sources, production pathways and effects on immune responses.

Authors:  Melissa Swiecki; Marco Colonna
Journal:  Curr Opin Virol       Date:  2011-11-25       Impact factor: 7.090

4.  TLR9 is actively recruited to Aspergillus fumigatus phagosomes and requires the N-terminal proteolytic cleavage domain for proper intracellular trafficking.

Authors:  Pia V Kasperkovitz; Michael L Cardenas; Jatin M Vyas
Journal:  J Immunol       Date:  2010-11-08       Impact factor: 5.422

Review 5.  Plasmacytoid dendritic cells: recent progress and open questions.

Authors:  Boris Reizis; Anna Bunin; Hiyaa S Ghosh; Kanako L Lewis; Vanja Sisirak
Journal:  Annu Rev Immunol       Date:  2011       Impact factor: 28.527

Review 6.  Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance.

Authors:  Melissa Swiecki; Marco Colonna
Journal:  Immunol Rev       Date:  2010-03       Impact factor: 12.988

7.  Hepatitis C virus fails to activate NF-κB signaling in plasmacytoid dendritic cells.

Authors:  Clélia Dental; Jonathan Florentin; Besma Aouar; Francoise Gondois-Rey; David Durantel; Thomas F Baumert; Jacques A Nunes; Daniel Olive; Ivan Hirsch; Ruzena Stranska
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

8.  Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding.

Authors:  Robert F Ashman; J Adam Goeken; Eicke Latz; Petar Lenert
Journal:  Int Immunol       Date:  2011-03       Impact factor: 4.823

Review 9.  Regulation of TLR7/9 signaling in plasmacytoid dendritic cells.

Authors:  Musheng Bao; Yong-Jun Liu
Journal:  Protein Cell       Date:  2012-11-07       Impact factor: 14.870

10.  CD82 controls CpG-dependent TLR9 signaling.

Authors:  Nida S Khan; Daniel P Lukason; Marianela Feliu; Rebecca A Ward; Allison K Lord; Jennifer L Reedy; Zaida G Ramirez-Ortiz; Jenny M Tam; Pia V Kasperkovitz; Paige E Negoro; Tammy D Vyas; Shuying Xu; Melanie M Brinkmann; Mridu Acharaya; Katerina Artavanis-Tsakonas; Eva-Maria Frickel; Christine E Becker; Zeina Dagher; You-Me Kim; Eicke Latz; Hidde L Ploegh; Michael K Mansour; Cindy K Miranti; Stuart M Levitz; Jatin M Vyas
Journal:  FASEB J       Date:  2019-08-13       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.